[go: up one dir, main page]

WO1999064046A8 - Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht¿3? - Google Patents

Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht¿3?

Info

Publication number
WO1999064046A8
WO1999064046A8 PCT/US1999/012768 US9912768W WO9964046A8 WO 1999064046 A8 WO1999064046 A8 WO 1999064046A8 US 9912768 W US9912768 W US 9912768W WO 9964046 A8 WO9964046 A8 WO 9964046A8
Authority
WO
WIPO (PCT)
Prior art keywords
agonists
receptors
antagonists
multivalent
partial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/012768
Other languages
English (en)
Other versions
WO1999064046A1 (fr
WO1999064046A9 (fr
Inventor
Guang Yang
Susan Meier-Davis
John H Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Advanced Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc filed Critical Advanced Medicine Inc
Priority to AU45514/99A priority Critical patent/AU4551499A/en
Priority to CA002321191A priority patent/CA2321191A1/fr
Priority to EP99928450A priority patent/EP1085888A1/fr
Publication of WO1999064046A1 publication Critical patent/WO1999064046A1/fr
Publication of WO1999064046A9 publication Critical patent/WO1999064046A9/fr
Anticipated expiration legal-status Critical
Publication of WO1999064046A8 publication Critical patent/WO1999064046A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés ou agents à plusieurs liaisons et qui se lient aux récepteurs 5-HT3. Ces composés comportent une pluralité de ligands dont chacun peut se lier à de tels récepteurs, modulant ainsi les fonctions ou processus biologiques de ces récepteurs. Chacun des ligands est attaché par covalence à un lieur ou à des lieurs qui peuvent être identiques ou différents, et ce, de façon à constituer un composé capable de liaisons multiples. Le choix du lieur est fait pour que le composé à liaisons multiples fasse preuve d'une modulation accrue des processus biologiques à médiation du récepteur 5-HT3.
PCT/US1999/012768 1998-06-08 1999-06-08 Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht¿3? Ceased WO1999064046A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU45514/99A AU4551499A (en) 1998-06-08 1999-06-08 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-HT3 receptors
CA002321191A CA2321191A1 (fr) 1998-06-08 1999-06-08 Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht3
EP99928450A EP1085888A1 (fr) 1998-06-08 1999-06-08 Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht 3?

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8846698P 1998-06-08 1998-06-08
US60/088,466 1998-06-08
US9293898P 1998-07-15 1998-07-15
US60/092,938 1998-07-15
US12028299P 1999-02-16 1999-02-16
US60/120,282 1999-02-16

Publications (3)

Publication Number Publication Date
WO1999064046A1 WO1999064046A1 (fr) 1999-12-16
WO1999064046A9 WO1999064046A9 (fr) 2000-04-20
WO1999064046A8 true WO1999064046A8 (fr) 2001-08-16

Family

ID=27375973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012768 Ceased WO1999064046A1 (fr) 1998-06-08 1999-06-08 Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht¿3?

Country Status (4)

Country Link
EP (1) EP1085888A1 (fr)
AU (1) AU4551499A (fr)
CA (1) CA2321191A1 (fr)
WO (1) WO1999064046A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100091A1 (fr) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Moyens et methodes de traitement ameliores utilisant des 'setrones'
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005802A1 (fr) * 1990-09-28 1992-04-16 Neorx Corporation Porteurs polymeres servant a la liberation d'agents a liaison covalente
WO1997035195A1 (fr) * 1996-03-19 1997-09-25 The Salk Institute For Biological Studies Procede d'identification in vitro de modulateurs de membres de la superfamille des recepteurs des steroides ou thyroides

Also Published As

Publication number Publication date
EP1085888A1 (fr) 2001-03-28
AU4551499A (en) 1999-12-30
WO1999064046A1 (fr) 1999-12-16
WO1999064046A9 (fr) 2000-04-20
CA2321191A1 (fr) 1999-12-16

Similar Documents

Publication Publication Date Title
SG164266A1 (en) Multibinding agents that modulate ppargamma and rxr receptors
WO2003050295A3 (fr) Essais et mises en oeuvre permettant de determiner et de moduler une activite de liaison hsp90
WO1999063932A3 (fr) Agents de liaison multiple, modulant le transporteur de 5-ht
WO1999003822A8 (fr) Ligands des recepteurs bicycliques metabotropiques du glutamate
ATE361364T1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
WO2003059251A3 (fr) Composes de ciblage d'anticorps
DK0915974T3 (da) Modificerede tie-2 receptor-ligander
BG103548A (en) Vitronectine receptor antagonists
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
WO2004035612A3 (fr) Composition, procede et utilisation de biomateriaux bifonctionnels
WO2001096565A3 (fr) Liant
GB9816575D0 (en) Novel compounds
WO2001064668A3 (fr) Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de l'argine-vasopressine
PT1137413E (pt) Antagonistas nao-peptidicos do receptor de glp-1 e metodos de utilizacao
BR9909522A (pt) Ligandos do receptor 5-ht1 azabicìclicos
WO1999064046A8 (fr) Agonistes polyvalents, agonistes partiels, agonistes inverses et antagonistes des recepteurs 5-ht¿3?
SE9804175D0 (sv) New assay
AUPP020297A0 (en) A novel receptor, and compounds which bind thereto
EE200300092A (et) EDb-fibronektiinidomeeni retseptor
CA2384911A1 (fr) Methode de criblage de ligands de liaison a la sous-unite .alpha.2.delta.-1
WO2001085930A3 (fr) Procedes et composes pour moduler la liaison ligand-recepteur de melanocortine et l'activite correspondante
DE60009063D1 (de) Liganden für den ip3 rezeptor
WO2001044439A3 (fr) Nouvelles analyses biologiques
WO2006010142A3 (fr) Composes de modulation des recepteurs des mineralocorticoides et methodes associees
EP0971885A4 (fr) Procede destine a la preparation de composes de type indane

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-130, DESCRIPTION, REPLACED BY NEW PAGES 1-130; PAGES 131-145, CLAIMS, REPLACED BY NEW PAGES131-145; PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2321191

Country of ref document: CA

Ref country code: CA

Ref document number: 2321191

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999928450

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999928450

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 50/99 UNDER (81) ADD "ZA"

WWW Wipo information: withdrawn in national office

Ref document number: 1999928450

Country of ref document: EP